cyclophosphamide + docetaxel + epidoxorubicin + pegfilgrastim

This is a combination chemotherapy and supportive care regimen consisting of four agents: - **Cyclophosphamide** is an alkylating agent that interferes with DNA replication and transcription, leading to cell death. - **Docetaxel** is a taxane-class antineoplastic that stabilizes microtubules, inhibiting cell division. - **Epidoxorubicin (epirubicin)** is an anthracycline antibiotic that intercalates into DNA, inhibits topoisomerase II, and generates free radicals causing cytotoxicity. - **Pegfilgrastim** is a long-acting recombinant human granulocyte colony-stimulating factor (G-CSF) analogue used as supportive care to stimulate neutrophil production and reduce the risk of chemotherapy-induced neutropenia. This combination has been studied primarily in breast cancer regimens. The inclusion of pegfilgrastim aims to ameliorate the myelosuppressive effects—especially neutropenia—caused by the cytotoxic agents[1][6][7]. The regimen may be administered in alternating or sequential schedules depending on protocol design. Pegfilgrastim does not have direct antitumor activity but supports hematopoietic recovery during intensive chemotherapy cycles.

Other names

AC-T with pegfilgrastimdoxorubicin/cyclophosphamide/docetaxel/pegfilgrastim combination